{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-090153","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.385806+00:00","generated_at":"2026-05-30T10:41:23.162205+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal Therapeutics raises $5.1M via ATM facility, selling 391,243 shares at $13.15","bullets":["Gross proceeds of $5.1M from sale of 391,243 shares at weighted avg price of $13.15/share.","Post-sale shares outstanding 1,496,771; cash balance approximately $7.4M as of Oct 23, 2024.","Proceeds to fund tecarfarin development and preparation for pivotal Phase 3 trial.","H.C. Wainwright acted as exclusive sales agent; shelf registration effective March 20, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-090153","json":"https://secwatch.observer/filing/0001213900-24-090153.json","markdown":"https://secwatch.observer/filing/0001213900-24-090153.md","text":"https://secwatch.observer/filing/0001213900-24-090153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/0001213900-24-090153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/ea0218502-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:41:23.162205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}